Efficacy and Safety of Recombinant Human Activated Protein C for Severe SepsisGordon R. Bernard, Charles J. Fisher, Jean‐Louis Vincent et al.|New England Journal of Medicine|2001Cited by 6.1k
Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients With Severe SepsisSteven M. Opal, for the ACCESS Study Group, Sandra Oeyen et al.|JAMA|2013Cited by 797
A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients With Sepsis and Suspected Disseminated Intravascular Coagulation*Jean‐Louis Vincent, Inder Kaul, M Ramesh et al.|Critical Care Medicine|2013Cited by 322
Long-Term Quality of Life Among Survivors of Severe Sepsis: Analyses of Two International Trials*Sachin Yende, Derek C. Angus, Shamly Austin et al.|Critical Care Medicine|2016Cited by 280
Phase 2 trial of eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist, in patients with severe sepsis*Mark Tidswell, Steven M. Opal, William Tillis et al.|Critical Care Medicine|2009Cited by 226